K Pharma,Inc. AI Stock Analysis
Want to see JP:4896 full AI Analyst Report?
K Pharma,Inc. (4896) AI Stock Analysis
K Pharma,Inc.
(TSE/TYO:4896)
The overall score of 39 is heavily weighed down by severe fundamental risks, including zero recent revenue generation, mounting debt, and substantial cash burn. While technical indicators show the stock is heavily oversold, the overarching bearish momentum and highly speculative valuation justify a near-minimum rating.
K Pharma,Inc. (4896) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 7.76B
- Dividend Yield
- ―
- Average Volume (3M)
- 21.81K
- Price to Earnings (P/E)
- -7.7
- Beta (1Y)
- 0.94
- Revenue Growth
- ―
- EPS Growth
- -20.34%
- Country
- Japan
- Employees
- 20
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
K Pharma,Inc. Business Overview & Revenue Model
Company Description
K Pharma, Inc., headquartered in Minato, Japan, was established in 2016 and operates within the Japanese market. The company is dedicated to the research, development, production, and sale of both regenerative medicines and pharmaceutical products. A...
K Pharma,Inc. Financial Statement Overview
Summary
Financial performance is scored at the absolute minimum due to a complete lack of recent recurring revenue, widening net losses, severe operating cash burn, and a newly leveraged balance sheet with rapidly eroding equity.
Income Statement
12Very NegativeBalance Sheet
32NegativeCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 1.00B | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 910.00M | 0 | -6.80M |
| EBITDA | -242.25M | -983.19M | -844.10M | 366.06M | -390.53M | -222.31M |
| Net Income | -250.58M | -993.23M | -846.46M | 260.33M | -392.43M | -228.72M |
Balance Sheet | ||||||
| Total Assets | 2.82B | 2.94B | 2.35B | 3.31B | 1.37B | 205.77M |
| Cash, Cash Equivalents and Short-Term Investments | 2.71B | 2.79B | 2.27B | 3.27B | 1.34B | 188.78M |
| Total Debt | 1.65B | 1.50B | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.81B | 1.67B | 94.76M | 209.13M | 38.30M | 26.88M |
| Stockholders Equity | 1.02B | 1.27B | 2.26B | 3.10B | 1.34B | 178.89M |
Cash Flow | ||||||
| Free Cash Flow | -929.19M | -929.19M | -998.21M | 444.62M | -393.44M | -196.32M |
| Operating Cash Flow | -918.00M | -918.00M | -983.72M | 454.43M | -363.48M | -196.32M |
| Investing Cash Flow | -54.68M | -54.68M | -14.49M | -11.10M | -32.74M | -250.00K |
| Financing Cash Flow | 1.50B | 1.50B | 0 | 1.49B | 1.54B | 368.20M |
K Pharma,Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4896, the sentiment is Neutral. The current price of 691.00 is below the 20-day moving average (MA) of 691.65, below the 50-day MA of 751.10, and below the 200-day MA of 740.61, indicating a bearish trend. The MACD of -21.43 indicates Negative momentum. The RSI at 46.46 is Neutral, neither overbought nor oversold. The STOCH value of 72.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4896.
K Pharma,Inc. Peers Comparison
Overall Rating
JP:709656Neutral
JP:488049Neutral
JP:458346.9Neutral
JP:777639Underperform- JP:489639Underperform
JP:459438Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:7096 | 56Neutral | JPY 6.84B | 46.53 | ― | ― | 2.55% | -43.06% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4880 | 49Neutral | JPY 5.58B | 56.54 | ― | 1.78% | -9.94% | ― |
| JP:4583 | 47Neutral | JPY 6.30B | -6.11 | ― | ― | -13.40% | 7.50% |
| JP:7776 | 39Underperform | JPY 6.78B | -5.83 | ― | ― | -56.16% | 3.12% |
| JP:4896 | 39Underperform | JPY 7.97B | -7.71 | ― | ― | ― | -20.34% |
| JP:4594 | 38Underperform | JPY 5.48B | -3.05 | ― | ― | -94.55% | -6.51% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4896 | K Pharma,Inc. | 691.00 | 41.00 | 6.31% | |
| JP:4583 | Chiome Bioscience Inc. | 76.00 | -47.00 | -38.21% | |
| JP:4594 | BrightPath Biotherapeutics Co.Ltd. | 39.00 | -19.00 | -32.76% | |
| JP:4880 | CellSource Co., Ltd. | 281.00 | -216.00 | -43.46% | |
| JP:7096 | StemCell Institute | 678.00 | -117.00 | -14.72% | |
| JP:7776 | CellSeed Inc. | 169.00 | -232.00 | -57.86% |
K Pharma,Inc. Corporate Events
K Pharma Records ¥54 Million Third-Quarter Impairment Loss
K Pharma, Inc. recorded a ¥54 million impairment loss on fixed assets for the third quarter ended September 30, 2026, and ¥61 million for the nine months ended that date. Recorded as an extraordinary loss, the charge mainly concerned research equipme...
K Pharma Reports Nine-Month 2026 Net Loss of ¥847 Million
K Pharma, Inc. is listed on the Tokyo Stock Exchange; the release does not identify its industry or primary products or services. It reported non-consolidated results for the nine months ended September 30, 2026, under Japanese GAAP.The company recor...
K Pharma revises fiscal 2026 loss forecasts lower
K Pharma, Inc., listed on the Tokyo Stock Exchange’s Growth Market under securities code 4896, revised its fiscal year ending December 31, 2026 forecast. The company lowered its projected operating loss to ¥1.093 billion from ¥1.520 billion, ordinary...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026